Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer

Thoracic Cancer

Volumn 6, Issue 4, 2015, Pages 407-412

  Xu, Qinghua ^a,e   Chen, Xiu ^b   Qian, Danwen ^c   Wang, Yongsheng ^d   Meng, Shuyan ^e   Liu, Hui ^a   Zhou, Caicun ^a,e  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b Zao Zhuang Municipal Hospital   (China)

^c Nanjing Red Cross Hospital   (China)

^d MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^e SHANGHAI PULMONARY HOSPITAL   (China)

Author keywords

EGFR TKIs; Leptomeningeal metastases; Non small cell lung cancer; Prognostic factors; WBRT

Indexed keywords

EID: 84934275316     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/1759-7714.12188     Document Type: Article

References (20)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. (Published erratum appears in CA Cancer J Clin 2011; 61: 134.) CA Cancer J Clin 2011; 61: 69-90.
2. Choong NW, Dietrich S, Seiwert TY etal. Gefitinib response of erlotinib-refractory lung cancer involving meninges - role of EGFR mutation. Nat Clin Pract Oncol 2006; 3: 50-57.
3. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999; 25: 103-119.
4. Omuro AM, Kris MG, Miller VA etal. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005;103: 2344 -2348.
5. Herrlinger U, Förschler H, Küker W etal. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 2004; 223: 167-178.
6. Groves MD. New strategies in the management of leptomeningeal metastases. Arch Neurol 2010; 67: 305-312.
7. Park JH, Kim YJ, Lee JO etal. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012; 76: 387-392.
8. Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol 2010; 136: 1729-1735.
9. Chamberlain MC, Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 1998; 55: 506-512.
10. Verger E, Gil M, Yaya R etal. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005; 61: 185-191.
11. Morris PG, Reiner AS, Szenberg OR etal. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012; 7: 382-385.
12. Porta R, Sánchez-Torres JM, Paz-Ares L etal. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011; 37: 624-631.
13. Sekine A, Kato T, Hagiwara E etal. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer 2012; 77: 64-69.
14. Sakai M, Ishikawa S, Ito H etal. Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib. Int J Clin Oncol 2006; 11: 243-245.
15. Li T. [Erlotinib as the second-line treatment for NSCLC patients of stage IIIb/IV.]. Zhongguo Fei Ai Za Zhi 2009; 12: 1297-1300. (In Chinese.)
16. Katayama T, Shimizu J, Suda K etal. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009; 4: 1415-1419.
17. Masuda T, Hattori N, Hamada A etal. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol 2011; 67: 1465-1469.
18. Welsh JW, Komaki R, Amini A etal. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013; 31: 895-902.
19. Waki F, Ando M, Takashima A etal. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol 2009; 93: 205-212.
20. Lee HL, Chung TS, Ting LL etal. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol 2012; 7: 181.